Medical Pharmacology Chapter 40: Immunosupressive Drugs
|
|
Defenses against antigenic insults:
Innate immune system
Adaptive immune system
Physical (skin)
Biochemical (e.g. complement, lysozyme)
Cellular (e.g. macrophages, neutrophils)
When the barrier is disrupted, bacterial destruction may occur by:
Lysozyme enzyme activity causes peptidoglycan cell wall component cleavage; also:
Split products from complement activation
Complement components: enhance macrophage and neutrophil phagocytosis by:
Acting as opsonins (C3b)
Attracting immunocytes to inflammatory sites (C3a, C5a)
Promoting bacterial lysis -- membrane attack complex generation
The adaptive immune system comes into play if the innate immune system has not managed the infection adequately.
Characteristics of the adaptive immune system
Specific responses to a variety managements
Discriminate between foreign ("nonself") and "self", i.e. host antigens
Exhibits "memory"; initiates an aggressive response to previously encountered antigen
Specific Immunity:-- requirements
Antigen presenting cells (APCs)
Langerhans cells
B lymphocytes
Dendritic cells
Macrophages
APCs digest antigens (enzymatically) producing peptides that:
Interact with T cell lymphocyte receptors (TCR) in association with class I and class II major histocompatibility complex proteins (MHC proteins)
T cell lymphocyte activation-- additional molecular dependencies:
CD4 on helper T cells
CD8 on cytotoxic T cells
LFA-1(lymphocyte functional antigen) and CD2 on both helper and cytotoxic T cells
Co-stimulatory molecules (B7.1 and B7.2) by cognate receptors on APCs
Thymic lymphocyte that bind to "self"-- eliminated by apotosis (negative selection)
Thymic lymphocytes that respond to foreign antigens in the presence of "self" MHC: retained (positive selection) and distributed to peripheral sites, available for later activation (after interacting with MHC-presented peptides):
Lymph node
Spleen
Peripheral blood
Musosa-associated lymphoid tissue
Subsets of T helper lymphocytes: discrimination based on cytokine secretion, after activation
|
|
|
Produces interferon-g (IFNg)
Produces interleukin-2 (IL-2)
Produces tumor necrosis factor-b (TNFb)
Induces cell-mediated immunity by activation of:
Cytotoxic T cells (CTL)
Natural killer (NK) cells
Macrophages
Produces (interleukins) IL-4, IL-5, IL-6 which in turn causes:
B-cell proliferation
Differentiation into antibody secreting plasma cells
T helper lymphocytes: mutual regulation
TH2 cells produce IL-10: inhibits TH1 cytokine production (down-regulates MHC expression by APCs)
TH1 interferon-g: inhibits TH2 cell proliferation
Other down-regulation/suppression factors (in some tissues)
Iransforming growth factor-b (TGF-b)
Down-regulates lymphocyte proliferation
Prostaglandin E2: down-regulates immune response
T helper lymphocytes: phenotype selection based on antigenic challenge
Extracellular bacteria: TH2 cytokine release
Intracellular organisms (e.g. Mycobacterium): TH1 cytokine release
Cytotoxic Consequences of Immune System Activation
Activated cytotoxic T cells (recognize processed peptides presented by virus-infected cells/tumor cells)
Induce target cell death by:
Perforin
Lytic granule enzymes ("granzymes")
Fas-Fas ligand (Fas-Fasl) apotosis pathway
Nitric oxide (may be released): inhibits cell enzymes
Viral Antigen Presentation (by virus-infected cells):
Nonapeptide fragments in the group of class 1 MHC molecules
Class I MHC molecules: presenting fragments of cellular antigens (virus/tumor antigens)--after Golgi apparatus processing
Class II MHC molecules: presenting antigen fragments from:
Internalized/enzymatically digested foreign antigens
Natural Killer Cells: (NK): (CD16+, CD56+, CD57+): possible role in tumor rejection/viral immunity; in vivo role uncertain
NK cells: large granular lymphocytes
Azurophilic cytoplasmic granules
Surface immunoglobulin negative
FC receptor-positive
Probably separate lymphoid cell lineage
NK cells: main precursor of lymphokine activated killer (LAK.)cells
LAK cells:
Stimulated by IL-2 (high concentration)
Referred to as (promiscuous killers) because:
Kill across MHC barriers
Kill target cells not expressing MHC
B lymphocytes: Humoral Immunity
|
|
Self-reactive B lymphocytes clonally deleted in the bone marrow
B-cell clones specific for foreign antigens -- retained/expanded
B-cell specificities due to:
Immunoglobulin gene rearrangement
These determinations occur prior to antigen exposure
Antigen specificity: T cells: genetically determined; derive from T-cell receptors
Sequence following Antigen binding to B-cell membrane immunoglobulin (IgM or IgD)
Antigen endocytosed, processed, presented to CD4+ T helper cells
T helper cells then stimulated to produce IL-4 and IL-5
Interleukins IL-4 and IL-5 stimulate:
B-cells proliferation
B-cell differentiation into memory B cells
Antibody secreting plasma cells
Primary antibody response: IgM-class immunoglobulins
Later antigenic stimulation leads to a "booster" response associated with:
Class switching (isotype switching) to produce IgG, IgA, IgD antibodies with various effector functions
Evolution over time:
Increased affinity; more efficient antigen binding
Antibodies activates opsonins to enhance phagocytosis, cellular cytotoxicity, and by activating complement promotes the inflammatory response which leads to bacterial lysis.
Primary Source: Barbuto, J.A.M, Akporiaye, E.T. and Hersh, E.M. Immunopharmacology, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 916-940
Haynes, B. F., Fauci, A.S. Disorders of the Immune System, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 1753-1776.
Carpenter, C. B. The Major Histocompatibility Gene Complex, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 1777-1782.
Cooper,M.D, and Lawton III, A. R. Primary Immune Deficiency Diseases, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 1783-1791
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals. |